CD300c2 Antibody (2799A) [Alexa Fluor® 647]

• Reactivity: Hu
• Applications: Flow
• Clone: 2799A
• Clonality: Monoclonal
• Host: Rabbit
• Conjugate: Alexa Fluor 647

CD300c2 Antibody (2799A) [Alexa Fluor® 647] Summary

• Additional Information: Recombinant Monoclonal Antibody.
• Immunogen: NS0-derived human CD300c protein
  Met29-Arg183
  Accession # Q08708
• Specificity: Detects recombinant human CD300c in direct ELISA. In direct ELISAs, no cross-reactivity with Human CD300a, CD300e, CD300LG and Mouse CD300c was detected
• Source: N/A
• Isotype: IgG
• Clonality: Monoclonal
• Host: Rabbit
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

Dilutions

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze.
  • 12 months from date of receipt, 2 to 8 °C as supplied.
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide

Notes

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for CD300c2 Antibody (2799A) [Alexa Fluor® 647]

• CD300c
• CLM6
• CLM-6
• CMRF35
• IGSF16

Background

Leukocyte mono-Ig-like receptor 2 (LMIR2; also CMRF-35, CMRF35-A antigen, and CD300c antigen) is a 23 kDa (predicted) type I transmembrane glycoprotein that belongs to the immunoregulatory signaling (IRS) family of molecules within the immunoglobulin (Ig) superfamily (1-4). Human LMIR2 is synthesized as a 224 amino acid (aa) precursor that has a 20 aa signal sequence, a 163 aa extracellular domain (ECD), a 21 aa transmembrane region, and a 20 aa cytoplasmic tail (SwissProt # Q08708). The ECD contains an Ig-like V-type domain (aa’s 22-128) and two N-linked glycosylation sites (aa’s 90 and 99). Downstream of the Ig V-domain, the membrane proximal region of LMIR2 (aa 128-183) contains a high proportion of proline (18%), serine (20%) and threonine (13%) residues (1). The transmembrane segment contains a charged glutamic acid that contributes to cell activation (1-3). Human LMIR2 shares 52% aa sequence identity with the mouse LMIR2, which is also known as CLM4. Human LMIR2 is 90% identical to human LMIR1 within the Ig-like domain. LMIR2 is present on the surface of natural killer cells, granulocytes, most myeloid cells, dendritic cells, and a subpopulation of T and B lymphocytes (1, 3). Mouse LMIR2 has the characteristics of an activatory molecule capable of inducing cellular activation and effector function in most cells and macrophages (3). The ligand for LMIR2 is presently unknown.

1. Jackson, D.G. et al. (1992) Eur. J. Immunol. 22:1157.
2. Clark, G.J. et al. (2001) Tissue Antigens 57:415.
3. Clark, G.J. et al. (2002) J. Biol. Regul. Homeost. Agents 16:233.
4. Daish, A. et al. (1993) Immunology 79:55.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Uniprot:
  • Q08708()